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Abstract. Infections caused by Human Cytomegalovirus 
(HCMV) and Epstein-Barr virus (EBV) are common in 
multiple transfused patients, such as patients with ß-
thalassaemia. The ability of the Polymerase Chain Reaction 
(PCR) to amplify HCMV and EBV DNA from blood and 
other samples makes this technique a valuable diagnostic tool 
for the detection of both viruses in the early stages of the 
infection. PCR was used for the amplification of a 435 bp 
region of the immediate early-1 (IE-1) gene of HCMV and a 
375 bp sequence from the EcoRI Β fragment of EBV 
genome. Blood samples from 80 patients with ß-thalassaemia 
were examined. HCMV was found in 14 and EBV in 12 
patients. The results obtained confirm the implications of 
HCMV and EBV in the diagnosis of viral infections in 
multiple transfused patients as well as the importance of PCR 
technique as a valuable diagnostic tool. 
Introduction 
HCMV and EBV are members of the herpes viruses family; 
HCMV is a ubiquitous viral pathogen provoking serious 
infections in specific populations such as immunosuppressed 
and immunocompromised patients, pregnant women, low 
birthweight neonates and multiple transfused patients (1). 
EBV is the causative agent of infectious mononucleosis and 
has been incriminated in the pathogenesis of Hodgkin's 
disease, Burkitt's lymphoma, nasopharyngeal carcinoma and 
lymphoproliferative disorders (2). Even though, primary 
infection occurring in childhood is mostly asymptomatic, in 
later childhood and adolescence it may result in 
lymphoproliferative diseases. Activation of latent EBV-
infected Β lymphocytes may also lead to the development of 
malignant lymphomas (3). 
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Current laboratory techniques used for the detection of 
HCMV and EBV are based on serological tests (e.g. ELISA, 
latex agglutination) while active infection can be determined 
using cell culture. However, serology as well as cell culture 
have disadvantages of major importance such as the high 
level of expertise required for the detection of antibodies, and 
the cost and time required for the cell culture (4,5). Recent 
advances in molecular biology have allowed in vitro 
amplification of specific nucleic acid sequences by the 
Polymerase Chain Reaction (PCR). The use of PCR for the 
detection of HCMV and EBV DNA have been previously 
reported (6,7). PCR provides a specific, rapid and sensitive 
means for the detection of viral genomes (8,9) as well as 
being a technique with other medical applications (10,11). 
We employed the PCR technique for the detection of HCMV 
and EBV DNA in peripheral blood leucocytes from 80 
frequently transfused patients with ß-thalassaemia. 
Materials and methods 
Patients. Blood samples were collected from selected groups 
of patients with homozygous ß-thalassaemia who undergo 
frequent transfusion treatment in the Thalassaemia Unit of 
the 1st Department of Pediatrics of the University of Athens 
at St. Sophia's Children Hospital. 80 patients with 
homozygous ß-thalassaemia were divided into four groups, as 
follows: group I, consisted of 10 patients with ß-thalassaemia 
and AIDS, group II, consisted of 15 patients with ß-
thalassaemia and increased transaminases, group III 49 
splenectomized patients with ß-ALT level thalassaemia, and 
group IV 6 patients awaiting for bone marrow transplantation. 
DM4 extraction. Leucocytes were isolated from 3 ml blood 
using Lymphoprep (Nycomed AS) and lysed with the 
addition of 400 μΐ TES buffer containing 100 μg/ml 
Proteinase K. After incubation at 37°C O/N samples were 
extracted once with phenol and once with phenol/chloroform. 
DNA was precipitated with the addition of 20 μΐ 5 M NaCl 
and 1 ml ethanol. DNA was recovered by centrifugation at 
13,000 rpm for 15 min at 4°C, washed once with 70% 
ethanol and resuspended in 100 μΐ of double-distilled water. 
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EBV genome 
114X106daltons 
172281 bp 
5' CGTGTGCGTCGTGCCGGGGCAGCCACTGG AAAGGAGCTTGCGATGGCCCTCCCAGGTCCT 3' 
5'GTGTGCGTCGTGCCGGGGCAGCCAC 3' 3' CCTCGAACGCTACCGGGAGGGTCCA 5' 
EBV 5' (102669-102694) ^-PRIMERS - ^ EBV 3' (103019-103044) 
PCR Amplification 
• 
5' GTGTGCGTCGTGCCGGGGCAGCCACTGG AAAGGAGCTTGCGATGGCCCTCCCAGGT 3' 
PCR product (375 bp) 
Figure 1. Schematic diagram of EBV oligonucleotide primers and the EBV genome. 
Control DNA. HCMV: DNA extracted from the CMV 
plasmid pRR 47 was used as a positive control. EBV: DNA 
extracted from peripheral blood leucocytes derived from a 
patient with infectious mononucleosis was used as positive 
control. 
Oligonucleotide primers. Two pairs of primers were used. 
One specific for the amplification of a 435 bp long sequence 
from the IE-1 gene of HCMV. This set of oligonucleotide 
primers, termed MIE-4 and MIE-5, has been previously 
described (12). The second set of primers, termed EBV-1 and 
EBV-2, was specific for the amplification of a 375 bp 
sequence from the EcoRI Β fragment of EBV (13). All the 
primer sequences used are shown in Table I. The 
oligonucleotide primers of EBV with the EBV genome are 
shown in Fig. 1. The HCMV primers with the HCMV IE-1 
sequence have been previously described (14). 
PCR amplification. HCMV: 500 ng DNA of each sample 
was amplified in a volume of 100 μΐ containing 200 μπι of 
dNTPs, 50 pmoles of each primer, 75 mM Tris-HCl (pH 8.4), 
200 mM (NH4),S04, 0.01% (w/v) Tween 20, 2.5 mM MgCl, 
and 2.5 units Taq polymerase (Advanced Biotechnologies). 
Amplification was performed in a thermal cycler (Perkin 
Elmer Cetus) using the following conditions: denaturation at 
94°C for 50 sec, annealing at 62°C for 30 sec and extension 
at 72°C for 50 sec, increasing the extension time by 1 sec per 
cycle. Samples were subjected to 40 cycles of amplification. 
EBV: PCR was performed with 500 ng genomic DNA in 100 
μΐ of the reaction containing, 10 mM Tris HCl at pH 8.3, 50 
mM KCl, 1.5 mM MgCl2, 0.001% gelatin, 200 mM dNTPs, 
40 pmoles of each primer and 2.5U of Taq polymerase 
(Advanced Biotechnologies). Samples, prior to the addition 
of Taq polymerase, were heated at 98°C for 5 min. 
Amplification was performed in a Perkin Elmer Cetus 
Thermal Cycler with the following parameters: denaturation 
at 95°C for 1 min, annealing and extension at 72°C for 1 min, 
for 35 cycles. 
Table I. Primer sequences for HCMV and EBV PCR. 
HCMV Immediate early-
Sense primer: 
Antisense primer: 
Product=435 bp 
EBV EcoRI Β fragment 
Sense primer: 
Antisense primer: 
Product=375 bp 
gene 
MIE-4 
MIE-5 
EBV 1 
EBV 2 
5' CCA AGC GGC CTC TGA TAA CCA AGC C 3' 
5' GGT CTC CTT CTC CTC CTA CCA CGA C 3' 
5' GTG TGC GTC GTG CCG GGG CAG CCA C 3' 
5' ACC TGG GAG GGC CAT CGC AAG CTC C 3' 
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Figure 2. Detection of HCMV DNA by PCR. Amplification products were 
electrophoresed through a 2% agarose gel. Lane 1: pUC18/HaeIII molecular 
marker, lane 2: negative control, lane 3: positive control, lanes 4,5: positive 
samples, lanes 6.7,8: negative samples. 
Twenty μΐ of the amplification products were run on a 2% 
agarose gel and visualised under UV illumination after 
staining with ethidium bromide. 
Results 
HCMV DNA was detected in 14 (17.5%) while EBV DNA 
in 12 (15%) out of the 80 patients. The presence of HCMV 
and/or EBV was judged from the amplification of a 435 bp 
long sequence and of 375 bp long sequence respectively 
(Figs. 2 and 3). HCMV DNA was detected in 2 out of 10 
patients in group I, 2 out of 15 patients in group II, 9 out of 
49 patients in group III and 1 out of 6 patients in group IV. 
Similarly, EBV DNA was detected in 4 out of 10 patients in 
group I, 2 out of 15 patients in group II, 4 out of 49 patients 
in group III and 2 out of 6 patients in group IV. Our results 
are summarised in Table II. None of the 80 examined 
patients were found to be co-infected with HCMV and EBV. 
Differences in the prevalence of HCMV and EBV infection 
among the groups studied were not found. 
Discussion 
HCMV and EBV can be transmitted via transfussion of blood 
or blood products given and/or bone marrow transplantation. 
Both viruses may cause serious infections in immuno-
suppressed and immunocompromised individuals and severe 
complications in transplant or multiple transfused patients 
who are under immunossuppression (15,16). In these cases, 
the early recognition of the viruses in the blood is essential. 
Tissue culture is time consuming, expensive and does not 
detect latent viruses. Serological tests are not reliable since 
the absence of increased levels of antibody to HCMV or to 
Figure 3. Detection of EBV DNA by PCR. Amplification products were 
electrophoresed through a 2% agarose gel. Lane I : pUC 18/HaeIII molecular 
marker, lane 2: negative control, lane 3: positive control, lanes 4.7: positive 
samples, lanes 5,6.8: negative samples. 
EBV may reflect impaired humoral immunity rather than 
lack of active infection. As much of the seropositive blood 
comes from blood donors who may not currently have an 
HCMV and/or EBV infection but who have been previously 
exposed to the virus(es), it seems apparent that the ability to 
detect the virus(es) itself/themselves in populations of blood 
donors has significant importance especially for certain 
groups of patients (17). It is strongly supported by two recent 
investigations which have shown that human cyto­
megalovirus DNA can be removed from donor blood by 
filtration and the potential for HCMV disease in very low 
birth weight infants can be reduced by removal of white 
blood cells from red cell concentrates (18,19). 
In this study, we examined 80 patients with homozygous 
ß-fhalassaemia who are on frequent transfusion treatment, 
with packed red cell preparations, leucocytes poor. HCMV 
DNA was detected in 14 out of the 80 (17.5%) while EBV 
DNA was detected in 12 out of the 80 examined patients 
(15%). Our data show that there is an implication of both 
HCMV and EBV in multiple transfused patients. As both 
viruses are associated with latent infections the detection of 
HCMV or EBV DNA does not indicate active viral infection. 
Application of the Reverse Transcription Polymerase Chain 
Reaction (RT-PCR) is required for the detection of mRNA 
transcripts which provide evidence of an active viral 
infection. However, in the case of latent viral infection, the 
immunosuppression which may arise due to red cell 
transfusions, may lead to reactivation of endogenous viruses. 
As, HCMV and EBV infections are not hospital based 
infections, it is essential that the HCMV and EBV status of 
Table II. Summary of results on the detection of HCMV and EBV by PCR. 
Groups studied Number of patients CMV positive EBV positive 
I. Patients with ß-thalassaemia and AIDS 10 
II. Patients with ß-thalassaemia and splenectomy 49 
III. Patients with ß-thalassaemia and increased transaminases 15 
IV. Patients with ß-thalassaemia undergoing marrow transplantation 6 
4 
4 
2 
2 
Total SO 14 12 
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blood used for transfusion to such patients is determined and 
that the clinical outcome is monitored (20). It must be 
stressed, that none of the patients studied had clinical signs of 
active infections, despite the fact that in the group of patients 
with anti-HIV antibodies immune deficiency was present. 
PCR has been proved to be a sensitive, accurate and 
specific method with two great advantages when applicable 
for the detection of viral genomes. It does not depend on the 
immune status of the patient that can be defective, either due 
to post-operative pharmaceutical immunosuppression or due 
to immune disorders and it is able to detect small amounts of 
viral copies in clinical specimens, including body fluids and 
biopsies, present either in latent or in replicative forms. 
Thus, PCR is a powerful diagnostic tool and may have an 
important role in the preparat ion of H C M V and EBV 
negative blood and blood products. By the use of HCMV and 
EBV negative blood the morbidity and mortality rate in 
suscept ible pat ients ( immunosuppressed and immuno-
compromised) is expected to decline. The prevalence of 
infect ion with H C M V and E B V , in pa t i en t s with ß-
thalassaemia is low compared to infection with HBV and 
HCV. This may be due to the fact, that during the last fifteen 
years, patients have been transfused with leucocyte poor, 
packed red cell preparations. 
References 
1. Smith KL: PCR detection of cytomegalovirus: A review. Br J 
Haematol 84: 187-190, 1993. 
2. Lager DS, Slagel DD, Burgart LJ: Detection of Epstein-Barr 
virus DNA in sequential renal transplant biopsy specimens 
using the polymerase chain reaction. Arch Pathol Lab Med 117: 
308-312, 1993. 
3. Smith RD: EBV: A ubiquitous agent that can immortalize cells. 
Hum Pathol 24: 233-234, 1993. 
4. Gulley ML, Raab-Traub N: Detection of EBV in human tissues 
by molecular genetic techniques. Arch Pathol Lab Med 117: 
1115-1120, 1993. 
5. Rasmussen L, Kelsall D and Nelson R: Virus specific IgG and 
IgM antibodies in normal and immunocompromised subjects 
infected with cytomegalovirus. J Inf Dis 145: 191-199, 1982. 
6. Shibata D, Martin WJ, Appleman MD, Causey DM, Leedom JM 
and Arnheim N: Detection of cytomegalovirus DNA in 
peripheral blood of patients infected with human 
immunodeficiency virus. J Inf Dis 158: 1185-1192, 1988. 
7. Telenti A, Marshall WF, Smith TF: Detection of Epstein-Barr 
virus by polymerase chain reaction. J Clin Microbiol 28: 2187-
2190, 1990. 
8. Nikolaidou A, Liloglou T, Malliri A, Ergazaki M, Tiniakos G, 
Tiniakos D and Spandidos DA: Detection of hepatitis Β virus 
DNA and mutations in K-ras and p53 genes in human 
hepatocellular carcinomas. Int J Oncol 3: 593-596, 1993. 
9. Rogers BB, Josephson SL and Mak SK: Detection of herpes 
simplex virus using the polymerase chain reaction followed by 
endonuclease cleavage. Am J Pathol 139: 1-6, 1991. 
10. Eisenstein BI: The Polymerase Chain Reaction: A new method 
of using molecular genetics for medical diagnosis. Ν Engl J 
Med 322: 178-183,1990. 
11. Wright PA, Wynford-Thomas D: The Polymerase Chain 
Reaction: Miracle or mirage? A critical review of its uses and 
limitations in diagnosis and research. J Pathol 162: 99-117, 
1990. 
12. Demmler GJ, Buffone GJ, Schimbor CM and May RA: 
Detection of cytomegalovirus in urine from newborns by using 
polymerase chain reaction DNA amplification. J Inf Dis 158: 
1177-1184, 1988. 
13. Rogers BB, Alpert LC, Hine EAS, Buffone GJ: Analysis of 
DNA in fresh and fixed tissue by the PCR. Am J Pathol 136: 
541-548, 1990. 
14. Ergazaki M, Xinarianos G, Koffa M, Liloglou Τ and 
Spandidos DA: Detection of human cytomegalovirus by the 
polymerase chain reaction in immunosuppressed and 
immunocompromised patients. Oncol Rep 1: 805-808, 1994. 
15. Liloglou T, Giannoudis A, Ergazaki M, Koffa M and 
Spandidos DA: Detection of Epstein Barr virus by the 
polymerase chain reaction in immunosuppressed and 
immunocompromised patients. Oncol Rep 1: 809-811, 1994. 
16. Cathomas G, Morris P, Pekle K, Cunningham I and Emanuel D: 
Rapid diagnosis of cytomegalovirus pneumonia in marrow 
transplant recipients by bronchoalveolar lavage using the 
polymerase chain reaction, virus culture, and the direct 
immunostaining of alveolar cells. Blood 81: 1909-1914, 1993. 
17. Bevan IS, Daw RA, Day PJR, Ala FA and Walker MR: 
Polymerase chain reaction for detection of human 
cytomegalovirus infection in a blood donor population. Br J 
Haematol 78: 94-99, 1991. 
18. Smith KL, Cobain Τ and Dunstan RA: Removal of 
cytomegalovirus DNA from donor blood by filtration. Br J 
Haematol 83: 640-642, 1993. 
19. Eisenfeld L, Silver H, McLaughlin J, Klevjer-Anderson P, 
Mayo D, Anderson J, et al: Prevention of transfusion-associated 
cytomegalovirus infection in neonatal patients by the removal of 
white cells from blood. Transfusion 32: 205-209, 1992. 
20. Demmler GJ, Yow MD, Spector SA, Reis SG, Brady MT, 
Anderson DC and Taber LH: Nosocomial cytomegalovirus 
infections within two hospitals caring for infants and children. J 
Infect Dis: 156:9-16, 1987. 
